

## Declaration of Interests Register

**TA Committee B**

**Publication Date: 18/11/2020**

**Topic: Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Gordon Cook	Clinical Expert	Direct -financial	Received consultancy fees received from Sanofi, Janssen & Celgene. Also receives fees for giving talks at Janssen.		25/09/2019		Interests declared and participated in part 1 of the meeting.  Agreed by chair Amanda Adler
Dr Neil Rabin	Clinical Expert	Direct financial & indirect	Received financial support from Celgene, Janssen-Cilag and Takeda to attend conferences, speak at educational meetings and advisory boards. He is also a member of advisory boards for Karyopharm and Amgen. He is an executive member of UKMF.		05/11/2019		Interests declared and participated in part 1 of the meeting.  Agreed by chair Amanda Adler

Mr Alan Chant	Patient Expert	Indirect Professional	Trustee of Myeloma UK		13/05/2020		Interests declared and participated in part 1 of the meeting.  Agreed by chair Amanda Adler
Shelagh McKinlay	Patient Expert	Indirect financial	Is employed by Myeloma UK who receive funding from several pharmaceutical companies, including Amgen, Janssen and Celgene		13/05/2020		Interests declared and participated in part 1 of the meeting.  Agreed by chair Amanda Adler
Peter Wheatley-Price	TAC B Committee Member	Direct financial	Employed by Takeda who manufacture a potential competitor product for isatuximab.		14/04/2020		Interests declared and did not attend the meeting/participate in the appraisal.  Agreed by chair Amanda Adler